PRINCIPLE trial shows significantly faster recovery with HCQ, with no safety concerns. Results withheld for 5 years. Other arms analyzed at the same time, not showing significantly faster recovery, were published during the pandemic.

RT @CovidAnalysis: @DrToddLee The other arms of this trial show that this reason is false. Comparing arms in the platform trials is very us….

RT @alexandrosM: This is the saddest sickest joke.

Details:

Withholding results showing significantly faster recovery and no safety concerns, from patients that risked their life to contribute to humanity, for a widely available very inexpensive treatment, during a pandemic killing millions is:.

RT @masimaux: I devoted this article to the unsung heroes of who have created invaluable - but unfortunately - mass….

7/ Xie et al. - Molecular Basis of High-Blood-Pressure-Enhanced and High-Fever-Temperature-Weakened Receptor-Binding Domain/Peptidase Domain Binding: A Molecular Dynamics Simulation Study. COVID-19 thermotherapy meta analysis.

6/ Meta-analysis of clinical studies with multiple thermotherapy methods - diathermy, heating pads, LF-ThMS - shows significantly lower COVID-19 risk via raising internal tissue temperature.

5/ Multiple clinical studies confirm that interventions that safely increase body/lung temperature, especially localized to respiratory tissues, can be beneficial for COVID-19 and other viral infections.

4/ The research provides additional evidence that fever is not a symptom to suppress, but an evolved defense mechanism that directly impairs viral binding.

3/ Lower temperature had the opposite effect - improving binding 8-fold and making binding energy more favorable, matching clinical observations of lower body temperature associated with poor outcomes.

2/ Fever temperatures destabilizes the binding interface - fewer hydrogen bonds, increased binding surface exposure, 3x lower binding probability, and significantly less favorable binding energy.

1/ An atom-level molecular dynamics study shows how fever temperatures disrupt SARS-CoV-2 binding to human cells, providing additional mechanistic evidence for the benefits of fever and thermotherapy for COVID-19.

New study provides atom-level insight into how fever and thermotherapy can inhibit COVID-19 infection. 🧵

Which low-cost treatments deserve full evidence review?. What was your experience with high-profit drugs—remdesivir, paxlovid, molnupiravir?. Did they prevent progression and long COVID, with no serious side‑effects? . How quickly could you access them after infection? 14/14.

References and more details:. 8,000+ proposed treatments:. NIH reviews:. NIH vitamin D review:. NIH zinc review:.

With new NIH leadership, will we finally see live evidence reviews of low‑cost therapies, a conflict‑free analysis team, and truly independent trials?. @DrJBhattacharya @NIH @SecKennedy 12/14

NIH panel members have extensive conflicts of interest, here are some examples. 11/14

Across all beneficial low-cost treatments we cover, there are 1,614 studies including 443 RCTs. NIH only reviewed 2% (7% of RCTs), with no quantitative analysis, and highly biased selection including many very low quality studies. 10/14.

For metformin they reference 2 of 104 studies (2 of 5 RCTs), while including a study reporting major outcome data that is impossible to be correct. For many others, no analysis at all. 9/14